Michalina Janiszewska, Ph.D.
Assistant Professor
Department:
SR-MM-JANISZEWSKA LAB
Business Phone:
(561) 228-2788
Business Email:
mjaniszewska@ufl.edu
About Michalina Janiszewska
Related Links:
Additional Positions:
Instructor of Medicine
2016 – 2018
·
Dana-Farber/Harvard Cancer Center
Postdoctoral Research Fellow
2012 – 2016
·
Dana-Farber/Harvard Cancer Center
Postdoctoral Research Fellow
2012 – 2012
·
CHUV- Lausanne University Hospital
Research Profile
Open Researcher and Contributor ID (ORCID)
0000-0002-8592-5146
Publications
Academic Articles
2024
PIK3CA inhibition in models of proliferative glomerulonephritis and lupus nephritis.
The Journal of clinical investigation.
134(15)
[DOI] 10.1172/JCI176402.
[PMID] 38842935.
2024
Spatial analysis of recurrent glioblastoma reveals perivascular niche organization.
JCI insight.
9(12)
[DOI] 10.1172/jci.insight.179853.
[PMID] 38805346.
2023
Single-cell heterogeneity of EGFR and CDK4 co-amplification is linked to immune infiltration in glioblastoma.
Cell reports.
42(3)
[DOI] 10.1016/j.celrep.2023.112235.
[PMID] 36920905.
2021
Adult precision medicine: learning from the past to enhance the future.
Neuro-oncology advances.
3(1)
[DOI] 10.1093/noajnl/vdaa145.
[PMID] 33543142.
2021
The impact of tumor epithelial and microenvironmental heterogeneity on treatment responses in HER2+ breast cancer.
JCI insight.
6(11)
[DOI] 10.1172/jci.insight.147617.
[PMID] 33886505.
2020
Cell adhesion in cancer: Beyond the migration of single cells.
The Journal of biological chemistry.
295(8):2495-2505
[DOI] 10.1074/jbc.REV119.007759.
[PMID] 31937589.
2020
Intratumor Heterogeneity: The Rosetta Stone of Therapy Resistance.
Cancer cell.
37(4):471-484
[DOI] 10.1016/j.ccell.2020.03.007.
[PMID] 32289271.
2020
The microcosmos of intratumor heterogeneity: the space-time of cancer evolution.
Oncogene.
39(10):2031-2039
[DOI] 10.1038/s41388-019-1127-5.
[PMID] 31784650.
2020
YAP-Mediated Recruitment of YY1 and EZH2 Represses Transcription of Key Cell-Cycle Regulators.
Cancer research.
80(12):2512-2522
[DOI] 10.1158/0008-5472.CAN-19-2415.
[PMID] 32409309.
2019
Subclonal cooperation drives metastasis by modulating local and systemic immune microenvironments.
Nature cell biology.
21(7):879-888
[DOI] 10.1038/s41556-019-0346-x.
[PMID] 31263265.
2018
A confetti trail of tumour evolution.
Nature cell biology.
20(6):639-641
[DOI] 10.1038/s41556-018-0110-7.
[PMID] 29802407.
2018
TRPS1 Is a Lineage-Specific Transcriptional Dependency in Breast Cancer.
Cell reports.
25(5):1255-1267.e5
[DOI] 10.1016/j.celrep.2018.10.023.
[PMID] 30380416.
2017
Classifying the evolutionary and ecological features of neoplasms.
Nature reviews. Cancer.
17(10):605-619
[DOI] 10.1038/nrc.2017.69.
[PMID] 28912577.
2016
IMPs: an RNA-binding protein family that provides a link between stem cell maintenance in normal development and cancer.
Genes & development.
30(22):2459-2474
[PMID] 27940961.
2016
Response and resistance to BET bromodomain inhibitors in triple-negative breast cancer.
Nature.
529(7586):413-417
[DOI] 10.1038/nature16508.
[PMID] 26735014.
2016
Spatial Proximity to Fibroblasts Impacts Molecular Features and Therapeutic Sensitivity of Breast Cancer Cells Influencing Clinical Outcomes.
Cancer research.
76(22):6495-6506
[DOI] 10.1158/0008-5472.CAN-16-1457.
[PMID] 27671678.
2016
The RNA Binding Protein IMP2 Preserves Glioblastoma Stem Cells by Preventing let-7 Target Gene Silencing.
Cell reports.
15(8):1634-47
[DOI] 10.1016/j.celrep.2016.04.086.
[PMID] 27184842.
2015
Clonal evolution in cancer: a tale of twisted twines.
Cell stem cell.
16(1):11-2
[DOI] 10.1016/j.stem.2014.12.011.
[PMID] 25575078.
2015
In situ single-cell analysis identifies heterogeneity for PIK3CA mutation and HER2 amplification in HER2-positive breast cancer.
Nature genetics.
47(10):1212-9
[DOI] 10.1038/ng.3391.
[PMID] 26301495.
2014
Tumor heterogeneity: the Lernaean hydra of oncology?
Oncology (Williston Park, N.Y.).
28(9):781-2, 784
[PMID] 25224477.
2012
Imp2 controls oxidative phosphorylation and is crucial for preserving glioblastoma cancer stem cells.
Genes & development.
26(17):1926-44
[DOI] 10.1101/gad.188292.112.
[PMID] 22899010.
2011
Let-7a is a direct EWS-FLI-1 target implicated in Ewing’s sarcoma development.
PloS one.
6(8)
[DOI] 10.1371/journal.pone.0023592.
[PMID] 21853155.
2010
EWS-FLI-1 modulates miRNA145 and SOX2 expression to initiate mesenchymal stem cell reprogramming toward Ewing sarcoma cancer stem cells.
Genes & development.
24(9):916-32
[DOI] 10.1101/gad.1899710.
[PMID] 20382729.
2010
Transportin regulates nuclear import of CD44.
The Journal of biological chemistry.
285(40):30548-57
[DOI] 10.1074/jbc.M109.075838.
[PMID] 20663864.
2009
Epigenetic features of human mesenchymal stem cells determine their permissiveness for induction of relevant transcriptional changes by SYT-SSX1.
PloS one.
4(11)
[DOI] 10.1371/journal.pone.0007904.
[PMID] 19936258.
2009
EZH2 is essential for glioblastoma cancer stem cell maintenance.
Cancer research.
69(24):9211-8
[DOI] 10.1158/0008-5472.CAN-09-1622.
[PMID] 19934320.
Grants
Jun 2024
ACTIVE
Oncofetal protein as a therapeutic target in pediatric brain tumors
Role: Principal Investigator
Funding: FL DEPT OF HLTH LIVE LIKE BELLA
Dec 2023
ACTIVE
Scott R. MacKenzie Foundation Final Grant application (Janiszewska #230017)
Role: Principal Investigator
Funding: UF FOUNDATION
via SCOTT R MACKENZIE FOUNDATION
Jan 2022
ACTIVE
American Cancer Society Institutional Research Grant
Role: Project Manager
Funding: AMERICAN CANCER SOCIETY
Education
Ph.D. in Life Sciences
2012
·
University of Lausanne
Master's of Science in Medical Biotechnology
2007
·
University of Wroclaw
Bachelor's of Science in Biotechnology
2005
·
University of Wroclaw
Contact Details
Phones:
- Business:
- (561) 228-2788
Emails:
- Business:
- mjaniszewska@ufl.edu
Addresses:
- Business Mailing:
-
Location C251
130 SCRIPPS WAY BLDG 2C1
JUPITER FL 33458